SASKATOON, June 19, 2013 /CNW/ - For the Canadians who have come to rely on medical marijuana for symptom management due to chronic disabilities and terminal illnesses, Prairie Plant Systems has been the sole supplier to Health Canada for the last 13 years, and has been producing safe and consistent medical marijuana for thousands of Canadian patients.
With today's official release of the Marihuana for Medical Purposes Regulations, the Harper Government has introduced revised regulations that will effectively create a new commercial industry responsible for providing access to quality controlled marijuana that is produced under the strictest of rules to ensure patient and public safety.
Prairie Plant Systems has already been operating under these strict manufacturing and quality controlled regulations and will continue to be Canada's leading provider of marijuana for medical purposes.
"These new regulations allow us the flexibility to clinically study and introduce several additional product types (strains or varieties), allowing us to customize different tetrahydrocannabinol (THC) and cannabidiol (CBD) levels, providing better symptom relief targeted to specific patient needs," said Brent Zettl, CEO, Prairie Plant Systems. "We welcome the opportunity to collaborate with the medical community and use our sophisticated research and development division to tailor personalized medicine for people with chronic disabilities and terminal illnesses, in an effort to improve quality of life."
About Prairie Plant Systems and CanniMed®
At Prairie Plant Systems we always put the safety of patients first by offering consistent and tested medical marijuana they can rely on for effective pain relief. Prairie Plant Systems' CanniMed® medical marijuana is developed through rigorous health and safety standards. At Prairie Plant Systems, medical marijuana is produced under Good Manufacturing Practices (GMP) regulations, the criteria used to manufacture all pharmaceuticals in Canada.
What sets Prairie Plant Systems apart is our clinical trial program where we are making a concerted effort to close the gap between anecdotal benefit and evidence based medicine in order to standardize care. To date, the pharmaceutical grade cannabis produced by Prairie Plant Systems has been used in published clinical trial results demonstrating the efficacy of smoked cannabis for chronic pain.1 Additional clinical trials are currently underway using different medical marijuana varieties, in controlled medical conditions.
1 Ware, M. A., Wang, T., Shapiro, S., Robinson, A. and others. (2010) Smoked Cannabis for Chronic Pain: a Randomized Controlled Trial. Canadian Medical Association Journal (CMAJ). 182:E694-E701.
Image with caption: "Prairie Plant Systems Comment on the New Medical Marijuana Regulations (CNW Group/Prairie Plant Systems Inc.)". Image available at: http://photos.newswire.ca/images/download/20130619_C9436_PHOTO_EN_28174.jpg
Image with caption: "Prairie Plant Systems Comment on the New Medical Marijuana Regulations (CNW Group/Prairie Plant Systems Inc.)". Image available at: http://photos.newswire.ca/images/download/20130619_C9436_PHOTO_EN_28175.jpg
SOURCE: Prairie Plant Systems Inc.
For further information:
Marketing & Communications Coordinator
Prairie Plant Systems Inc.
Dara Willis Communications